首款国产九价HPV疫苗在京开打，9-45岁女性可接种

Core Insights - The launch of China's first domestically developed nine-valent HPV vaccine marks a significant milestone in cervical cancer prevention for women aged 9 to 45 in Beijing, providing a more comprehensive and cost-effective option compared to imported vaccines [1][2] - The vaccine, developed using a novel E. coli expression system, underwent 18 years of research and over one million independent tests, demonstrating safety and efficacy approved by the National Medical Products Administration [1] - The pricing for the vaccine is set at 499 yuan per dose, with a total cost of 998 yuan for a two-dose regimen for females aged 9-17, and 1497 yuan for a three-dose regimen for those aged 18-45 [1] Group 1 - The nine-valent HPV vaccine is the second of its kind globally and aims to break the long-standing monopoly of imported vaccines in the market [1] - Clinical trial data supporting the vaccine's safety and efficacy has been published in The Lancet Infectious Diseases [1] - The vaccine's introduction is expected to strengthen health protection for women in China against cervical cancer and related diseases [1] Group 2 - The vaccination service for the domestic nine-valent HPV vaccine has been fully launched in Beijing, with the first batch delivered to community health service centers across the city [2] - Preparations by local health departments are in place to ensure an orderly vaccination process [2] - Citizens can access information and make appointments for vaccination through the Jingtong mini-program, the Capital Vaccine Service APP, or by contacting local community health service centers [2]